Getinge Group: Annual General Meeting in Getinge AB

Regulatory News:

The shareholders of Getinge AB (publ)(STO:GETIB) are invited to attend the Annual General Meeting to be held on Wednesday 21 April 2010 at 4.00 p.m., in Kongresshallen, Hotel Tylösand, Halmstad.

As stated in the notice to convene the Annual General Meeting the following matters, among others, are proposed:

A dividend of SEK 2.75 per share is proposed.

Cecilia Daun Wennborg is proposed as new member of the Board.

Re-election is proposed to take place of the Board members Carl Bennet, Johan Bygge, Rolf Ekedahl, Carola Lemne, Johan Malmquist and Johan Stern. As Chairman of the Board, Carl Bennet is proposed to be re-elected. Margareta Norell Bergendahl has declined re-election.

Cecilia Daun Wennborg, age 45 and Bachelor of Economics, is, up to and including March 2010, Vice President of Ambea AB. She is also Board member of Hakon Invest AB and Vårdföretagarna. Cecilia Daun Wennborg has previously been CEO of Carema Vård och Omsorg AB, CFO of Ambea AB and Carema Vård och Omsorg AB, acting CEO of Skandiabanken, head of the Swedish operations of Skandia and CEO of Skandia Link.

The notice to attend the Annual General Meeting is attached in its entirety to this press release.

Getinge, 15 March 2010
Getinge AB (publ)

This information is such that Getinge AB (publ) must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was submitted for publication on 15 March 2010, at 08:30 a.m.

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions and intensive care.

This information was brought to you by Cision http://www.cisionwire.com